In its release on the CARDIO-TTRansform data, the ESC echoed AZ and Ionis’ point that Wainua suppressed circulating serum TTR ...

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...

Mimrylo marks the second FDA new drug approval that Takeda has secured since CEO Julie Kim officially took the reins in June ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

Biogen’s late-stage lupus candidates may not have crossed the FDA finish line yet, but the company has already hit the ground ...

The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several ...

By Alicia Cowley, MD, MBA, Medical Director, Phreesia Network Solutions | Endemic media and broad reach each do half the job.

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as ...

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across ...

RevMed’s leadership, too, highlighted the significance of Rasonque’s approval in a call with investors yesterday.

McKesson Corporation is expanding its drug development and commercialization capacity to the tune of $2.25 billion. | The ...